{{Rsnum
|rsid=1074287
|Gene=OPRM1
|Chromosome=6
|position=154027674
|Orientation=plus
|GMAF=0.287
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=OPRM1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 55.4 | 41.5 | 3.1
| HCB | 65.9 | 31.8 | 2.3
| JPT | 83.7 | 16.3 | 0.0
| YRI | 25.4 | 46.0 | 28.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 65.9 | 31.8 | 2.3
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20560679
|Title=Response to Methadone Maintenance Treatment is Associated with the MYOCD and GRM6 Genes
}}{{PMID Auto
|PMID=19053977
|Title=OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.
|OA=1
}}

{{PMID Auto
|PMID=19103668
|Title=Expansion of the human mu-opioid receptor gene architecture: novel functional variants.
|OA=1
}}{{PMID Auto
|PMID=22406240
|Title=Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients.
}}